BioCardia, Inc. · NASDAQ:BCDA

BioCardia — Investor Presentation (November 2026)

23 slides from BioCardia's investor presentation, November 2026

  1. Slide 1: Corporate Presentation

    Slide 1: Corporate Presentation

    Developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases Corporate Presentation BioCardia, Inc. (NASDAQ: BCDA) Peter Altman, PhD President and CEO paltman@biocardia.com www.biocardia.com 05295-BB (MKT) Corporate Presentation November 2026 1

  2. Slide 2: Presentation Content and Disclaimer

    Slide 2: Presentation Content and Disclaimer

    Presentation Content and Disclaimer Presentation Content No part of this presentation or the information herein may be reproduced, photocopied, redistributed or passed on, directly or indirectly, to any other person, or published, in whole or in part, for any purpose without the consent of BioCardia

  3. Slide 3: Problem: Heart failure, a disease with enormous unmet need

    Slide 3: Problem: Heart failure, a disease with enormous unmet need

    Problem: Heart failure, a disease with enormous unmet need • 56.2 million people worldwide have HF. 1 • In the United States, HF costs are projected to increase to $70 billion in 2030, half related to hospitalization.1 • In Japan, one million patents have heart failure with 31 to 47% having ischemic

  4. Slide 4: Proprietary Platforms Overview

    Slide 4: Proprietary Platforms Overview

    Proprietary Platforms Overview  CardiAMP® Autologous Mononuclear Cells - lead program for ischemic heart failure of reduced ejection fraction (HFrEF), second program for related indication of chronic myocardial ischemia  Pipeline-in-a-Product: Off the Shelf MSC Therapies - Advancing CardiALLO and

  5. Slide 5: Potential Solution: Enhancing Microvascular Function

    Slide 5: Potential Solution: Enhancing Microvascular Function

    Potential Solution: Enhancing Microvascular Function  New mechanism of action: o improve microvascular capillary density o reduce fibrosis o prevent adverse remodeling  Mechanism driven primarily by cell mediated paracrine signaling  Not intended to regenerate new myocardium Silva et al. Tex Hear

  6. Slide 6: CardiAMP Cell Therapy: Lead Program

    Slide 6: CardiAMP Cell Therapy: Lead Program

    CardiAMP® Cell Therapy: Lead Program FDA Breakthrough Designation / Has CMS Reimbursement Autologous Cell Therapy For ischemic HFrEF 05295-BB (MKT) Corporate Presentation November 2026 6

  7. Slide 7: CardiAMP System Development Status

    Slide 7: CardiAMP System Development Status

    CardiAMP System Development Status 200 Procedures and Counting FDA Breakthrough Device Designation granted based on results from Phase I and II trials. CMS Reimbursement Code C9782 for CardiAMP Cell Therapy for both treated and control patients at $20,000 ($35,000 for a treatment and a control) TABM

  8. Slide 8: Phase III CardiAMP HF Trial

    Slide 8: Phase III CardiAMP HF Trial

    Phase III CardiAMP HF Trial 05295-BB (MKT) Corporate Presentation November 2026 8

  9. Slide 9: CardiAMP HF Phase III Results in Patients with NTproBNP/BNP >500 pg/ml

    Slide 9: CardiAMP HF Phase III Results in Patients with NTproBNP/BNP >500 pg/ml

    CardiAMP HF Phase III Results in Patients with NTproBNP/BNP >500 pg/ml Composite outcome of three tiers – all benefit treatment A C A C Tier 3 6MWD MLHFQ +14m +0m 9.9 pts improvement WR=1.61 WR=2.02 CI 0.84-3.08 CI 1.01- 4.03 p=0.15 p =0.04 HTx = Heart Transplant; LVAD = Left ventricular Assist Devi

  10. Slide 10: CardiAMP HF Phase III Results: LVEDVi and LVESVi

    Slide 10: CardiAMP HF Phase III Results: LVEDVi and LVESVi

    CardiAMP HF Phase III Results in Patients with NTproBNP/BNP >500 pg/ml Left Ventricular End Diastolic Volume Index (LVEDVi) and Left Ventricular End Diastolic Volume Index (LVESVi) show prevention of negative heart enlargement. This has long been known to align with positive outcomes.** LVEDVi LVESV

  11. Slide 11: CardiAMP Key clinical insights

    Slide 11: CardiAMP Key clinical insights

    CardiAMP Key clinical insights  Benefit seen across patients in three trials* • Reduced mortality and non-fatal major adverse cardiac events • Improved heart function • Improved quality of life  Heart failure patients are heterogeneous Analysis suggests greater benefit in patients with both high c

  12. Slide 12: CardiAMP HF Pathways to Approval and Reimbursement: Japan

    Slide 12: CardiAMP HF Pathways to Approval and Reimbursement: Japan

    CardiAMP HF Pathways to Approval and Reimbursement JAPAN  Japan Pharmaceutical and Medical Devices Agency (PMDA) has said they are likely to accept existing evidence of safety and efficacy as sufficient for market release. o Initial indication identical to CardiAMP HF Trial with elevated NTproBNP.

  13. Slide 13: CardiAMP HF Pathways to Approval and Reimbursement: Japan

    Slide 13: CardiAMP HF Pathways to Approval and Reimbursement: Japan

    CardiAMP HF Pathways to Approval and Reimbursement JAPAN  Target initial population for CardiAMP cell therapy o In Japan, total ischemic HFrEF patients are ~ 300,000 and anticipate ~20,000 initial reachable patients with unmet need as discussed with PMDA. A cardiac cell therapy patch that is surgic

  14. Slide 14: CardiAMP HF Pathways to Approval and Reimbursement: USA

    Slide 14: CardiAMP HF Pathways to Approval and Reimbursement: USA

    CardiAMP HF Pathways to Approval and Reimbursement USA  Target initial population for CardiAMP cell therapy o Patients with ischemic heart failure, on guideline directed medical therapy but still having biomarker evidence of active heart stress ~ 1 million patients in USA 1, 2 o Reimbursement in US

  15. Slide 15: Ongoing Confirmatory CardiAMP HF II Clinical Trial

    Slide 15: Ongoing Confirmatory CardiAMP HF II Clinical Trial

    Ongoing Confirmatory CardiAMP HF II Clinical Trial  Double Blind Procedure Placebo Controlled Randomized (1:1) Trial (NCT06258447) o NYHA Class II and III, EF< 40%, Ischemic etiology, with elevated NTproBNP o Patients on stable Guideline Directed Medical Therapy o One month screening to baseline de

  16. Slide 16: 2nd Platform: Allogeneic Mesenchymal Stem Cells

    Slide 16: 2nd Platform: Allogeneic Mesenchymal Stem Cells

    2nd Platform Allogeneic Mesenchymal Stem Cells being advanced for Cardiac and Pulmonary indications 05295-BB (MKT) Corporate Presentation November 2026 16

  17. Slide 17: CardiALLO Allogeneic Cell Therapy Strategic Optionality

    Slide 17: CardiALLO Allogeneic Cell Therapy Strategic Optionality

    CardiALLO Allogeneic Cell Therapy Strategic Optionality Pipeline-in-a-Product: Off the Shelf MSC Therapies  Donor derived mesenchymal cells manufactured and cryopreserved for therapy o Potential advantages  Off the shelf availability – reduces clinical procedural logistics  No need for performing

  18. Slide 18: Allogeneic Mesenchymal Stem Cells in Heart Failure (BCDA-03) TRIDENT Study

    Slide 18: Allogeneic Mesenchymal Stem Cells in Heart Failure (BCDA-03) TRIDENT Study

    Allogeneic Mesenchymal Stem Cells in Heart Failure (BCDA-03) Phase I/II TRIDENT Clinical Study, NCT02013674 Allogeneic MSC at 20M and 100M cells (N= 30) delivered at ten sites with Helix. Primary outcome measures: thirty-day post catheterization incidence of predefined treatment-emergent serious adv

  19. Slide 19: 3rd Platform: Helix cardiac biotherapeutic delivery

    Slide 19: 3rd Platform: Helix cardiac biotherapeutic delivery

    3rd Platform Helix cardiac biotherapeutic delivery for cell, gene, and protein delivery to the heart 05295-BB (MKT) Corporate Presentation November 2026 19

  20. Slide 20: Delivery as a Differentiator

    Slide 20: Delivery as a Differentiator

    Delivery as a Differentiator Pipeline-in-a-Product: Local Delivery to the Heart Precision Transendocardial Delivery • Proprietary catheter-based delivery systems for targeted myocardial injection • Delivery quality recognized as a key variable in cardiac cell and gene therapy outcomes • Helix cathet

  21. Slide 21: Intellectual Property Overview

    Slide 21: Intellectual Property Overview

    Intellectual Property Overview  Exclusive rights to over 60 patents and patent applications in USA, Europe, China, India, and Japan with goal to protect the company’s platform and therapeutic initiatives. 05295-BB (MKT) Corporate Presentation November 2026 21

  22. Slide 22: Executive Management Team

    Slide 22: Executive Management Team

    Executive Management Team Peter Altman David McClung Debby Holmes- Edward Gillis Higgin CEO CFO VP Clinical SVP Devices Board of Directors:  Andrew Blank, Chairman of the Board, CEO Archive America, Board Member Neumentum  Jay Moyes, Chairman Audit Committee, Board Member Puma Biotechnology, Inc.

  23. Slide 23: Financial Data and Significant Anticipated Catalysts

    Slide 23: Financial Data and Significant Anticipated Catalysts

    Financial Data and Significant Anticipated Catalysts Year Year Through CardiAMP Cell Therapy Ended Ended Q3 Q1 ‘27 Peer Reviewed Manuscript 2024 2025 2026 Q1 ‘27 Japan PMDA Submission for Approval ($mm) ($mm) ($mm) Helix Delivery Net Loss $7.9 $8.2 $5.7 Q4 ‘26 FDA Pre-Sub Meeting for De Novo Approva

Source: company website

More decks from BioCardia, Inc.

All 18 BioCardia decks